Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, ZFN, TALEN), By Delivery Method, By Application, By Mode, By End-use, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Genome Editing market size is expected to hit around USD 25.4 billion by 2030 from valued at USD 4.7 billion in 2021 and growing at a CAGR of 28.4% from 2022 to 2030.

Key Takeaways:

  • The CRISPR/Cas9 technology segment accounted for the significant revenue share in 2020
  • The CRISPR/Cas9 technology has proven its efficiency as a promising gene-editing tool owing to its advantages over conventional gene modification methods
  • One of the significant advantages includes simultaneous modification of multiple target genes using this technology
  • The ex-vivo delivery method accounted for a major share owing to its ease of DNA modification which resulted in its wide application for genome editing purposes
  • Genetic engineering, particularly, cell line engineering dominated the market
  • High penetration of gene-manipulation tools in stem cell research has contributed to this dominance
  • The application of CRISPR technology has enhanced the productivity of CHO cell lines consequently increasing its application in biopharmaceutical production
  • Besides, animal genetic engineering is witnessing the growing application of gene-alteration tools for various purposes such as the development of animal models to mirror human diseases
  • Moreover, the Cas protein system is gaining traction in the development of point-of-care diagnostics, thereby driving investment flow in diagnostic applications
  • Biotechnology and pharmaceutical companies are the key end-users of the market as these are adopted these technologies for the development of novel therapeutics to a major extent
  • Also, the COVID-19 pandemic has driven the investments in this space to develop rapid molecular diagnostic tests based on gene editing by biotechnology companies
  • North America dominated the 2020 global market owing to the strong research as well as the commercial base for various gene alteration tools
  • Moreover, the U.S. is the major contributor in the region with the high adoption of molecular scissor tools across research
  • This is indicated by the increasing number of genome editing-based research publications in the country
  • In Asia Pacific, the market is anticipated to witness the fastest growth rate over the forecast period
  • China is reported to be the first country to have successfully transferred genetically edited cells into humans, to boost immunity and treat lung cancer, thereby driving the market
  • Licensing agreements is the major strategy undertaken by operating companies in this space to strengthen their market position

Report Scope of the Genome Editing Market

Report Coverage

Details

Market Size

USD 25.4 Billion by 2030

Growth Rate

CAGR of 28.4% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

 Technology, delivery method, application, mode, end-use and Region,

Companies Mentioned

 Merck KGaA; Cibus; Recombinetics, Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics, Inc.; Caribou Biosciences, Inc.; Cellectis; AstraZeneca; Takara Bio USA; Horizon Discovery Group plc; Integrated DNA Technologies, Inc.; Egenesis Inc.; GenScript; New England Biolabs; OriGene Technologies, Inc.; Lonza; Thermo Fisher Scientific, Inc.

Increasing implementation of CRISPR genome editing technology coupled with rising synthetic gene demand in diverse biotechnology domains has primarily driven the market growth over the past few years.

Furthermore, the development of CRISPR -based novel diagnostic tools to mitigate the adverse impact of the COVID-19 pandemic is driving the market. For instance, in March 2021, a team of researchers from the Nanyang Technological University developed a diagnostic test - VaNGuard (Variant Nucleotide Guard) based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, thereby increasing the adoption of CRISPR genome editing technology in the diagnostics arena.

Apart from this, continuous technological advancements in gene-editing tools are a major contributing factor for revenue generation in this market. For instance, in April 2021, researchers from Wyss Institute for Biologically Inspired Engineering at Harvard developed Retron Library Recombineering (RLR) - a new gene-editing tool that enabled the performance of millions of genetic experiments simultaneously, thereby providing better editing rates.

Moreover, the market is witnessing intensified competition among the market players owing to the expanding applications of genome editing tools. There has been an increased focus on the highly adaptable CRISPR technology. For instance, in April 2021, Vertex Pharmaceuticals paid USD 900 million to CRISPR Therapeutics to develop, manufacture and commercialize CRISPR-Cas9 gene-edited therapy for beta-thalassemia and sickle-cell disease. Such initiatives are anticipated to propel market growth.

The expanding gene therapy marketspace has shown significant interest in gene manipulation technologies, thus augmenting the revenue growth. In April 2021, a genome editing consortium announced its plan to develop a new genome editing 'toolkit'. This is aimed to boost gene therapy development. The amount of USD 190 million was granted to the Somatic Cell Genome Editing Consortium for the development of genome editing methods and approaches.

Delivery Method Insights

The ex-vivo delivery method segment dominated the market and accounted for the largest revenue share of 58.2% in 2021. This can be attributed to the advantages offered by this mode type such as ease of control in DNA modification. The growing clinical trial pipeline that deploys genome editing tools has spurred the ex-vivo delivery segment growth with the increased usage of this delivery method.

On the other hand, the in-vivo gene delivery method accounted for lower revenue generation because of challenges that occurred during the process such as off-target effects. However, focused efforts are being taken to overcome the challenges with growing clinical trials focused on easy target tissues using in-vivo delivery.

Application Insights

The developments in gene editing systems have revolutionized the genetic engineering space, with cell line engineering at the forefront, accounting for the largest revenue share of 59.8% in 2021. This can be attributed to the rapidly growing field of gene and stem cell therapy. The usage of CRISPR gene editing in human-induced pluripotent stem cells (hiPSCs) related programs has important implications in stem cell research for the treatment of various diseases. The clinical application segment dominated the market and accounted for the significant revenue share in 2020.

Furthermore, the CRISPR technology is widely being applied to enhance the productivity of CHO cell lines. These cell lines are prominently used in the production of large molecule therapeutics. Thus, with the application of the CRISPR tool, the biopharmaceutical marketspace is witnessing advancements consequently driving the market for genome editing.

Besides, genetic engineering, genome editing technologies have high potential growth in clinical applications such as diagnostics and therapy development. For instance, an ongoing clinical trial sponsored by Cellectis S.A. is aimed to evaluate the efficacy and safety of UCART123 in patients with R/R Acute Myeloid Leukemia. This therapy is based on TALEN gene-editing technology.

End-use Insights

The biotechnology and pharmaceutical companies segment dominated the market and accounted for the largest revenue share of 50.4% in 2021. The presence of a growing number of research activities for novel therapeutic development is the major factor contributing to the segment revenue generation. Moreover, global pharmaceutical companies are collaborating with emerging companies to develop novel technologies.

For instance, in April 2021, CANbridge Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc signed a strategic collaboration and licensing agreement to address rare and serious diseases. Through this agreement, CANbridge Pharmaceuticals, Inc. gained rights to the latter company’s gene-editing platforms. Similarly, in October 2020, Scribe Therapeutics collaborated with Biogen for the development of CRISPR-based genetic medicines for neurological diseases such as Amyotrophic Lateral Sclerosis.

On the other hand, government research and academic institutes are anticipated to witness healthy growth in the near future owing to the increasing uptake of gene-editing technologies in university-level projects. Active engagement of research institutes further supplements the segment growth. For instance, research institutes such as Baylor College of Medicine, Rice University, and Whitehead Institute are actively involved in efforts to advance genome editing.

Mode Insights

The contract-based genome editing segment dominated the market and accounted for the largest revenue share of 52.9% in 2021. The high cost of associated infrastructure coupled with increasing collaborations between market entities has resulted in a significant market share of contract services in the global market. For instance, in September 2020, ERS Genomics and Applied StemCell, Inc. signed an agreement for the commercialization of genome editing services.

Similarly, in November 2020, Eli Lilly and the company collaborated with Precision BioSciences, Inc. to use the latter company’s proprietary ARCUS genome editing platform to develop potential in-vivo therapeutics for genetic disorders. Such collaborations have intensified the market competition leading to organic revenue growth.

Well-established companies such as Merck KGaA and Thermo Fisher Scientific are involved in providing custom vectors for cell line editing and engineering. Such services are anticipated to witness growth in the coming years, thereby fueling revenue growth. The rapidly growing demand from gene therapy market players would also propel the revenue generation for contract manufacturers.

Regional Insights

North America dominated the genome editing market and accounted for the largest revenue share of 39.4% in 2021. The presence of strong research, as well as a commercial base for advanced therapy development coupled with a high number of clinical trials being conducted for gene and stem cell therapies in the region, has majorly contributed to the dominance of the market in the region.

Furthermore, the increasing number of patents awarded to U.S.-based key players has also accelerated the uptake of these tools in the country leading to significant market growth. For instance, Merck KGaA recently announced that two patents of the company have been approved in the U.S. for CRISPR gene-editing technologies.

On the other hand, in Asia Pacific, the market is anticipated to witness the fastest growth rate throughout the forecast period. In November 2021, China announced its ten most significant advances in the agriculture sector, out of which one was gene-editing technology, thus representing the high market penetration of this space in the country.

Some of the prominent players in the Genome Editing Market include:

  • Merck KGaA
  • Cibus, Recombinetics, Inc.
  • Sangamo
  • Editas Medicine
  • Precision Biosciences
  • CRISPR Therapeutics
  • Intellia Therapeutics, Inc.
  • Caribou Biosciences, Inc.
  • Cellectis S.A.
  • AstraZeneca
  • Takara Bio USA
  • Horizon Discovery Group plc
  • Integrated DNA Technologies, Inc.
  • Egenesis Inc.
  • GenScript
  • New England Biolabs
  • OriGene Technologies, Inc.
  • Lonza
  • Thermo Fisher Scientific, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Genome Editing market

  • Technology
    • Meganucleases
    • (CRISPR)/Cas9
    • TALENs/MegaTALs
    • ZFN
    • Others
  • Delivery Method
    • Ex-vivo
    • In-vivo
  • Mode
    • Contract
    • In-house
  • End-use
    • Biotechnology and pharmaceutical companies
    • Academic and government research institutes
    • Contract research organizations
  • Application
    • Genetic Engineering
      • Cell line engineering
      • Animal genetic engineering
      • Plant genetic engineering
      • Others
    • Clinical Applications
      • Diagnostics
      • Therapy Development

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Genome Editing industry analysis from 2022 to 2030 to identify the prevailing Genome Editing industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Genome Editing industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Genome Editing industry trends, key players, market segments, application areas, and market growth strategies.

Chapter 1. Introduction
                 1.1 Information Procurement
                 1.2 Data Analysis
                 1.3 Market segmentation & scope
                 1.4 Market definition
                 1.5 Information procurement
                       1.5.1 Purchased database
                       1.5.2 nova one advisor’s internal database
                       1.5.3 Secondary sources & Third-Party perspectives
                       1.5.4 Primary research
                 1.6 Information analysis
                       1.6.1 Data analysis models
                 1.7 Market formulation & data visualization
                 1.8 Data validation & publishing
Chapter 2 Genome Editing Market: Executive Summary
                 2.1 Genome Editing Market Outlook, 2017 - 2030
                 2.2 Segment Outlook
Chapter 3 Genome Editing Market: Industry Outlook
                 3.1 Market Pyramid Analysis
                       3.1.1 Parent Market
                       3.1.2 Ancillary Market
                 3.2 Market Dynamics Analysis
                       3.2.1 Market Driver Analysis
                            3.2.1.1 Success in pre-clinical models drives demands for genome editing therapeutics
                            3.2.1.2 Rising competition amongst market participants for business development
                            3.2.1.3 Easy editing solutions for the development of therapeutics for a broad range of diseases
                            3.2.1.4 Increasing demand for synthetic genes and genetically modified organisms
                            3.2.1.5 Technological advancements in gene editing technologies
                            3.2.1.6 Rising adoption in agricultural biotechnology
                       3.2.2 Market Restraint Analysis
                            3.2.2.1 Challenges with respect to clinical translation
                            3.2.2.2 Regulatory, scientific, and ethical challenges pertaining to the use of genetically modified products
                            3.2.2.3 Off-target effects of CRISPR technology
                 3.3 Penetration &Growth Prospect MappingforTechnology, 2020
                 3.4 Genome editing -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
                 3.5 Industry Analysis - Porter’s
                 3.6 Genome Editing Technologies: Pipeline Analysis
                       3.6.1 Sangamo
                       3.6.2 Cellectis
                       3.6.3 Calyxt
                       3.6.4 bluebird bio
                       3.6.5 Editas Medicine
                       3.6.6 Intellia Therapeutics, Inc.
                       3.6.7 CRISPR Therapeutics
                       3.6.8 Precision Biosciences
                       3.6.9 Precision Biosciences (Non-medical domain)
                       3.6.10 Caribou Biosciences
                       3.6.11 Cibus
                       3.6.12 Recombinetics, Inc
                 3.7 Intellectual Property
                 3.8 Regulatory Issues
                       3.8.1 Orphan diseases
                       3.8.2 Germline editing
                       3.8.3 Safety issues
                 3.9 COVID-19 Impact Analysis
Chapter 4 Genome Editing Market: Technology Business Analysis
                 4.1 Genome Editing Market: Technology Movement Analysis
                 4.2 Genome EditingTechnology Comparison
                 4.3 (CRISPR)/Cas9
                       4.3.1 Global (CRISPR)/Cas9 market, 2017 - 2030
                 4.4 TALENs/MegaTALs
                       4.4.1 Global TALENs/MegaTALs market, 2017 - 2030
                 4.5 ZFN
                       4.5.1 Global ZFN market, 2017 - 2030
                 4.6 Meganucleases
                       4.6.1 Global Meganucleases market, 2017 - 2030
                 4.7 Other Technologies
                       4.7.1 Global other technologies market, 2017 - 2030
Chapter 5 Genome Editing Market: Delivery Method Business Analysis
                 5.1 Genome Editing Market: Delivery Method Movement Analysis
                       5.1.1 Comparison of Delivery Methods
                            5.1.1.1 Viral delivery
                                  5.1.1.1.1 AAV (Adeno Associated Virus)
                                  5.1.1.1.2 IDLV (Integrase Deficient Lentivirus).
                            5.1.1.2 Non-viral delivery
                                  5.1.1.2.1 Lipid Mediated
                                  5.1.1.2.2 Electroporation
                 5.2 Ex-vivo
                       5.2.1 Global ex-vivo delivery market, 2017 - 2030
                 5.3 In-vivo
                       5.3.1 Global in-vivo delivery market, 2017 - 2030
Chapter 6 Genome Editing Market: Application Business Analysis
                 6.1 Market: ApplicationMovement Analysis
                 6.2 Genetic Engineering
                       6.2.1 Market, 2017 - 2030
                            6.2.1.1 Cell line engineering
                                  6.2.1.1.1 Market, 2017 - 2030
                            6.2.1.2 Animal genetic engineering
                                  6.2.1.2.1 Market, 2017 - 2030
                            6.2.1.3 Plant genetic engineering
                                  6.2.1.3.1 Market, 2017 - 2030
                            6.2.1.4 Others
                                  6.2.1.4.1 Global others market, 2017 - 2030
                 6.3 Clinical Applications
                       6.3.1 Market for clinical applications, 2017 - 2030
                            6.3.1.1 Diagnostics
                                  6.3.1.1.1 Market for diagnostics applications, 2017 - 2030
                            6.3.1.2 Therapy Development
                                  6.3.1.2.1 Market for therapy development applications, 2017 - 2030
Chapter 7 Genome Editing Market: End-Use Business Analysis
                 7.1 Market: End-use Movement Analysis
                 7.2 Biotechnology & Pharmaceutical Companies
                       7.2.1 Market, 2017 - 2030
                 7.3 Academic & Government Research Institutes
                       7.3.1 Market, 2017 - 2030
                 7.4 Contract Research Organizations (CROs)
                       7.4.1 Market, 2017 - 2030
Chapter 8 Genome Editing Market: Mode Business Analysis
                 8.1 Market: Mode Movement Analysis
                 8.2 In-house
                       8.2.1 Market, 2017 - 2030
                 8.3 Contract
                       8.3.1 Market, 2017 - 2030
Chapter 9 Genome Editing Market: Regional Business Analysis
                 9.1 Market Share By Region, 2020 & 2030
                 9.2 North America
                       9.2.1 Market, 2017 - 2030
                       9.2.2 U.S.
                       9.2.2.1 U.S. genome editing market, by technology, 2017 - 2030
                            9.2.2.2 U.S. genome editing market, by delivery method, 2017 - 2030
                            9.2.2.3 U.S. genome editing market, by application, 2017 - 2030
                            9.2.2.4 U.S. genome editing market, by end-use, 2017 - 2030
                            9.2.2.5 U.S. genome editing market, by mode, 2017 - 2030
                       9.2.3 Canada
                            9.2.3.1 Canada genome editing market, by technology, 2017 - 2030
                            9.2.3.2 Canada genome editing market, by delivery method, 2017 - 2030
                            9.2.3.3 Canada genome editing market, by application, 2017 - 2030
                            9.2.3.4 Canada genome editing market, by end-use, 2017 - 2030
                            9.2.3.5 Canada genome editing market, by mode, 2017 - 2030
                 9.3 Europe
                       9.3.1 Europe genome editing market, 2017 - 2030
                       9.3.2 Germany
                            9.3.2.1 Germany genome editing market, by technology, 2017 - 2030
                            9.3.3.2 Germany genome editing market, by delivery method, 2017 - 2030
                            9.3.3.3 Germany genome editing market, by application, 2017 - 2030
                            9.3.3.4 Germany genome editing market, by end-use, 2017 - 2030
                            9.3.3.5 Germany genome editing market, by mode, 2017 - 2030
                       9.3.3 U.K.
                            9.3.3.1 U.K. genome editing market, by technology, 2017 - 2030
                            9.3.3.2 U.K. genome editing market, by delivery method, 2017 - 2030
                            9.3.3.3 U.K. genome editing market, by application, 2017 - 2030
                            9.3.3.4 U.K. genome editing market, by end-use, 2017 - 2030
                            9.3.3.5 U.K. genome editing market, by mode, 2017 - 2030
                       9.3.4 Italy
                            9.3.4.1 Italy genome editing market, by technology, 2017 - 2030
                            9.3.4.2 Italy genome editing market, by delivery method, 2017 - 2030
                            9.3.4.3 Italy genome editing market, by application, 2017 - 2030
                            9.3.4.4 Italy genome editing market, by end-use, 2017 - 2030
                            9.3.4.5 Italy genome editing market, by mode, 2017 - 2030
                       9.3.5 France
                            9.3.5.1 France genome editing market, by technology, 2017 - 2030
                            9.3.5.2 France genome editing market, by delivery method, 2017 - 2030
                            9.3.5.3 France genome editing market, by application, 2017 - 2030
                            9.3.5.4 France genome editing market, by end-use, 2017 - 2030
                            9.3.5.5 France genome editing market, by mode, 2017 - 2030
                       9.3.6 Spain
                            9.3.6.1 Spain genome editing market, by technology, 2017 - 2030
                            9.3.6.2 Spain genome editing market, by delivery method, 2017 - 2030
                            9.3.6.3 Spain genome editing market, by application, 2017 - 2030
                            9.3.6.4 Spain genome editing market, by end-use, 2017 - 2030
                            9.3.6.5 Spain genome editing market, by mode, 2017 - 2030
                 9.4 Asia Pacific
                       9.4.1 Asia Pacific genome editing market, 2017 - 2030
                       9.4.2 Japan
                            9.4.2.1 Japan genome editing market, by technology, 2017 - 2030
                            9.4.2.2 Japan genome editing market, by delivery method, 2017 - 2030
                            9.4.2.3 Japan genome editing market, by application, 2017 - 2030
                            9.4.2.4 Japan genome editing market, by end-use, 2017 - 2030
                            9.4.2.5 Japan genome editing market, by mode, 2017 - 2030
                       9.4.3 China
                            9.4.3.1 China genome editing market, by technology, 2017 - 2030
                            9.4.3.2 China genome editing market, by delivery method, 2017 - 2030
                            9.4.3.3 China genome editing market, by application, 2017 - 2030
                            9.4.3.4 China genome editing market, by end-use, 2017 - 2030
                            9.4.3.5 China genome editing market, by mode, 2017 - 2030
                       9.4.4 South Korea
                            9.4.4.1 South Korea genome editing market, by technology, 2017 - 2030
                            9.4.4.2 South Korea genome editing market, by delivery method, 2017 - 2030
                            9.4.4.3 South Korea genome editing market, by application, 2017 - 2030
                            9.4.4.4 South Korea genome editing market, by end-use, 2017 - 2030
                            9.4.4.5 South Korea genome editing market, by mode, 2017 - 2030
                       9.4.5 India
                            9.4.5.1 India genome editing market, by technology, 2017 - 2030
                            9.4.5.2 India genome editing market, by delivery method, 2017 - 2030
                            9.4.5.3 India genome editing market, by application, 2017 - 2030
                            9.4.5.4 India genome editing market, by end-use, 2017 - 2030
                            9.4.5.5 India genome editing market, by mode, 2017 - 2030
                 9.5 Latin America
                       9.5.1 Latin America genome editing market, 2017 - 2030
                       9.5.2 Brazil
                            9.5.2.1 Brazil genome editing market, by technology, 2017 - 2030
                            9.5.2.2 Brazil genome editing market, by delivery method, 2017 - 2030
                            9.5.2.3 Brazil genome editing market, by application, 2017 - 2030
                            9.5.2.4 Brazil genome editing market, by end-use, 2017 - 2030
                            9.5.2.5 Brazil genome editing market, by mode, 2017 - 2030
                       9.5.3 Mexico
                            9.5.3.1 Mexico genome editing market, by technology, 2017 - 2030
                            9.5.3.2 Mexico genome editing market, by delivery method, 2017 - 2030
                            9.5.3.3 Mexico genome editing market, by application, 2017 - 2030
                            9.5.3.4 Mexico genome editing market, by end-use, 2017 - 2030
                            9.5.3.5 Mexico genome editing market, by mode, 2017 - 2030
                 9.6 Middle East & Africa
                       9.6.1 Middle East & Africa genome editing market, 2017 - 2030
                       9.6.2 South Africa
                            9.6.2.1 South Africa genome editing market, by technology, 2017 - 2030
                            9.6.2.2 South Africa genome editing market, by delivery method, 2017 - 2030
                            9.6.2.3 South Africa genome editing market, by application, 2017 - 2030
                            9.6.2.4 South Africa genome editing market, by end-use, 2017 - 2030
                            9.6.2.5 South Africa genome editing market, by mode, 2017 - 2030
                       9.6.3 Saudi Arabia
                            9.6.3.1 Saudi Arabia genome editing market, by technology, 2017 - 2030
                            9.6.3.2 Saudi Arabia genome editing market, by delivery method, 2017 - 2030
                            9.6.3.3 Saudi Arabia genome editing market, by application, 2017 - 2030
                            9.6.3.4 Saudi Arabia genome editing market, by end-use, 2017 - 2030
                            9.6.3.5 Saudi Arabia genome editing market, by mode, 2017 - 2030
Chapter 10 Genome Editing Market: Competitive Landscape
                 10.1 Strategy Framework
                 10.2 Market Participation Categorization
                 10.3 Strategic Alliance Analysis
                       10.3.1 Mergers & Acquisitions
                       10.3.2 Technological Collaborations
                       10.3.3 Licensing and partnership
                 10.4 Recent Developments & Impact Analysis
                 10.5 List of Potential End-users
                 10.6 Company Profiles
                       10.6.1 Merck KGaA
                            10.6.1.1 Company overview
                                  10.6.1.1.1 Sigma-Aldrich Co. LLC
                            10.6.1.2 Financial performance
                            10.6.1.3 Product benchmarking
                            10.6.1.4 Strategic initiatives
                       10.6.2 Cibus
                            10.6.2.1 Company overview
                                  10.6.2.1.1 Nucelis
                            10.6.2.2 Financial performance
                            10.6.2.3 Product benchmarking
                            10.6.2.4 Strategic initiatives
                       10.6.3 Recombinetics, Inc
                            10.6.3.1 Company overview
                            10.6.3.2 Financial performance
                            10.6.3.3 Product benchmarking
                            10.6.3.4 Strategic initiatives
                       10.6.4 Sangamo
                            10.6.4.1 Company overview
                            10.6.4.2 Financial performance
                            10.6.4.3 Product benchmarking
                            10.6.4.4 Strategic initiatives
                       10.6.5 Editas Medicine
                            10.6.5.1 Company overview
                            10.6.5.2 Financial performance
                            10.6.5.3 Product benchmarking
                            10.6.5.4 Strategic initiatives
                       10.6.6 Precision Biosciences
                            10.6.6.1 Company overview
                            10.6.6.2 Financial performance
                            10.6.6.3 Product benchmarking
                            10.6.6.4 Strategic initiatives
                       10.6.7 CRISPR THERAPEUTICS
                            10.6.7.1 Company overview
                            10.6.7.2 Financial performance
                            10.6.7.3 Product benchmarking
                            10.6.7.4 Strategic initiatives
                       10.6.8 Intellia Therapeutics, Inc.
                            10.6.8.1 Company overview
                            10.6.8.2 Financial performance
                            10.6.8.3 Product benchmarking
                            10.6.8.4 Strategic initiatives
                       10.6.9 Caribou Biosciences, Inc
                            10.6.9.1 Company overview
                            10.6.9.2 Financial performance
                            10.6.9.3 Product benchmarking
                            10.6.9.4 Strategic initiatives
                       10.6.10 Cellectis
                            10.6.10.1 Company overview
                            10.6.10.2 Financial performance
                            10.6.10.3 Product benchmarking
                            10.6.10.4 Strategic initiatives
                       10.6.11 AstraZeneca
                            10.6.11.1 Company overview
                            10.6.11.2 Financial performance
                            10.6.11.3 Product benchmarking
                            10.6.11.4 Strategic initiatives
                       10.6.12 Takara Bio Inc.
                            10.6.12.1 Company overview
                            10.6.12.2 Financial performance
                            10.6.12.3 Product benchmarking
                            10.6.12.4 Strategic initiatives
                       10.6.13 Horizon Discovery Group plc
                            10.6.13.1 Company overview
                            10.6.13.2 Financial performance
                            10.6.13.3 Product benchmarking
                            10.6.13.4 Strategic initiatives
                       10.6.14 Integrated DNA Technologies, Inc.
                            10.6.14.1 Company overview
                            10.6.14.2 Financial performance
                            10.6.14.3 Product benchmarking
                       10.6.15 Transposagen Biopharmaceuticals, Inc.
                            10.6.15.1 Company overview
                            10.6.15.2 Financial performance
                            10.6.15.3 Product benchmarking
                       10.6.16 GenScript
                            10.6.16.1 Company overview
                            10.6.16.2 Financial performance
                            10.6.16.3 Product benchmarking
                            10.6.16.4 Strategic initiatives
                       10.6.17 New England Biolabs
                            10.6.17.1 Company overview
                            10.6.17.2 Financial performance
                            10.6.17.3 Product benchmarking
                            10.6.17.4 Strategic initiatives
                       10.6.18 OriGene Technologies, Inc.
                            10.6.18.1 Company overview
                            10.6.18.2 Financial performance
                            10.6.18.3 Product benchmarking
                            10.6.18.4 Strategic initiatives
                       10.6.19 bluebird bio, Inc.
                            10.6.19.1 Company overview
                            10.6.19.2 Financial performance
                            10.6.19.3 Product benchmarking
                            10.6.19.4 Strategic initiatives
                       10.6.20 Lonza
                            10.6.20.1 Company overview
                            10.6.20.2 Financial performance
                            10.6.20.3 Product benchmarking
                            10.6.20.4 Strategic initiatives
                       10.6.21 Thermo Fisher Scientific, Inc.
                            10.6.21.1 Company overview
                            10.6.21.2 Financial performance
                            10.6.21.3 Product benchmarking
                            10.6.21.4 Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers